News for CureVac N.V. (5CV.DE)

Operator: Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.

CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ETCompany ParticipantsSarah Fakih - Vice President, Corporate...

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblas

CureVac (CVAC) reports significant revenue boost in 2024, largely driven by a €400 million payment from GSK. The company maintains a strong cash posit

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerPr

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday. Shares of Argan, Inc. AGX rose sharply during Friday's session following ...

Shares of Portage Biotech Inc. (PRTG) were up over 100% in after-hours trading on Thursday, following promising preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor, given as a single agent or in combination with anti-PD-1 antibody in a murine model of mesothelioma.

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amend

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual prope

CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ETCompany ParticipantsSarah Fakih - Vice President of Corporate...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense...

CureVac N.V. recently secured a significant deal with GSK, boosting its cash reserves. Learn more about CVAC stock and the impact of this deal.

GSK advances mRNA flu vaccine after positive Phase 2 data

Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Click here to ready my MRNA update.

CureVac appoints new director to enhance R&D

London-based VivoPower International PLC (VVPR) is up over 121 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.